NCT06302374View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

March 4, 2023

Primary Completion Date

November 1, 2023

Study Completion Date

February 19, 2024

Conditions
Tetanus
Interventions
BIOLOGICAL

GR2001

intramuscular injection

BIOLOGICAL

Placebo

intramuscular injection

BIOLOGICAL

HTIG

intramuscular injection

BIOLOGICAL

Tetanus Toxoid

intramuscular injection

Trial Locations (1)

200040

Huashan Hospital affiliated of Fudan University, Shanghai

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY